Abstract
To compare the risk of psychiatric hospitalization among adults with schizophrenia using aripiprazole with an ingestible sensor (AS), to those on oral atypical antipsychotic (OAA) treatment in the real world.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have